Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…
The number of diagnosed prevalent cases of JIA in the countries under study will remain relatively stable over the 20 years of our forecast period. Of the countries considered in this analysis…
Clarivate Epidemiology’s coverage of juvenile idiopathic arthritis (JIA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of nonalcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of fibromyalgia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
The number of total prevalent cases of fibromyalgia in the countries under study will remain relatively stable over the 20 years of our forecast period. Of the countries considered in this…
Clarivate Epidemiology’s coverage of Peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…
Clarivate Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD…
Clarivate Epidemiology’s coverage of nonalcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of renal anemia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of bipolar disorder (BPD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France,…
Clarivate Epidemiology’s coverage of amyloidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of MN…